Epidemiological, endocrine and metabolic features in Turner syndrome

European Journal of Endocrinology

Volumn 151, Issue 6, 2004, Pages 657-687

  Gravholt, Claus Højbjerg ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; CARBOHYDRATE; CORTICOTROPIN; ESTRADIOL; ESTROGEN; GESTAGEN; GROWTH HORMONE; INSULIN; LIVER ENZYME; NORETHISTERONE; OXANDROLONE; SEX HORMONE; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; TESTOSTERONE;

ADRENAL FUNCTION; ANTHROPOMETRY; BODY COMPOSITION; BODY HEIGHT; BONE GROWTH; BONE MINERALIZATION; BREAST CANCER; CARBOHYDRATE METABOLISM; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; ENDOCRINE DISEASE; FEMALE; FEMALE INFERTILITY; FITNESS; FRACTURE; GENETIC DISORDER; GONADAL DYSGENESIS; GROWTH HORMONE RELEASE; GROWTH RETARDATION; HEART FUNCTION; HORMONE ACTION; HORMONE RELEASE; HORMONE SUBSTITUTION; HUMAN; HYPOPHYSIS GONAD SYSTEM; INCIDENCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIVER DYSFUNCTION; LIVER FUNCTION; LOW DRUG DOSE; LUNG EMBOLISM; MORBIDITY; MORTALITY; NONHUMAN; PERINATAL PERIOD; PRENATAL PERIOD; PREVALENCE; PRIORITY JOURNAL; PUBERTY; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; SHORT STATURE; STROKE; SYMPTOMATOLOGY; THYROID FUNCTION; TURNER SYNDROME; X CHROMOSOME ABERRATION;

ADULT; ANTHROPOMETRY; BODY COMPOSITION; FEMALE; GROWTH HORMONE; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; OVARY; PITUITARY GLAND; PREGNANCY; PRENATAL DIAGNOSIS; TURNER SYNDROME;

EID: 11844290658     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1510657     Document Type: Review

References (351)

1. Turner HH. A syndrome of infantilism, congenital webbed neck, and cubitus valgus. Endocrinology 1938 23 566-574.
2. Seresevskij NA. In relation to the question of a connection between congential abnormalities and endocrinopathies. 1925. The Russian Endocrinological Society.
3. Ullrich O. Uber typische kombinationsbilder multipler abartungen. Zeitschrift fur Kinderheilkunde 1930 49 271-276.
4. Saenger P, Wikland KA, Conway GS, Davenport M, Gravholt CH, Hintz R, Hovatta O, Hultcrantz M, Landin-Wilhelmsen K, Lin A, Lippe B, Pasquino AM, Ranke MB, Rosenfeld R & Silberbach M. Recommendations for the diagnosis and management of Turner syndrome. Journal of Clinical Endocrinology and Metabolism 2001 86 3061-3069.
5. Nicolaides KH, Heath V & Cicero S. Increased fetal nuchal translucency at 11-14 weeks. Prenatal Diagnosis 2002 22 308-315.
6. Hyett JA, Noble PL, Snijders RJ, Montenegro N & Nicolaides KH. Fetal heart rate in trisomy 21 and other chromosomal abnormalities at 10-14 weeks of gestation. Ultrasound in Obstetrics & Gynecology 1996 7 239-244.
7. Haak MC, Bartelings MM, Gittenberger-De Groot AC & van Vugt JM. Cardiac malformations in first-trimester fetuses with increased nuchal translucency: ultrasound diagnosis and postmortem morphology. Ultrasound in Obstetrics & Gynecology 2002 20 14-21.
8. Gravholt CH, Juul S, Naeraa RW & Hansen J. Morbidity in Turner syndrome. Journal of Clinical Epidemiology 1998 51 147-158.
9. Held KR, Kerber S, Kaminsky E, Singh S, Goetz P, Seemanova E & Goedde HW. Mosaicism in 45,X Turner syndrome: does survival in early pregnancy depend on the presence of two sex chromosomes? Human Genetics 1992 88 288-294.
10. Fernandez R, Mendez J & Pasaro E. Turner syndrome: a study of chromosomal mosaicism. Human Genetics 1996 98 29-35.
11. Gravholt CH, Juul S, Naeraa RW & Hansen J. Prenatal and post-natal prevalence of Turner's syndrome: a registry study. British Medical Journal 1996 312 16-21.
12. Hook EB & Warburton D. The distribution of chromosomal gen5otypes associated with Turner's syndrome: livebirth prevalence rates and evidence for diminished fetal mortality and severity in genotypes associated with structural X abnormalities or mosaicism. Human Genetics 1983 64 24-27.
13. Amiel A, Kidron D, Kedar I, Gaber E, Reish O & Fejgin MD. Are all phenotypically-normal Turner syndrome fetuses mosaics? Prenatal Diagnosis 1996 16 791-795.
14. Koeberl DD, McGillivray B & Sybert VP. Prenatal diagnosis of 45,X/46,XX mosaicism and 45,X: implications for postnatal outcome. American Journal of Human Genetics 1995 57 661-666.
15. Blair J, Tolmie J, Hollman AS & Donaldson MD. Phenotype, ovarian function, and growth in patients with 45,X/47,XXX Turner mosaicism: implications for prenatal counselling and estrogen therapy at puberty. Journal of Pediatrics 2001 139 724-728.
16. Huang B, Thangavelu M, Bhatt S, Sandlin J & Wang S. Prenatal diagnosis of 45,X and 45,X mosaicism: the need for thorough cytogenetic and clinical evaluations. Prenatal Diagnosis 2002 22 105-110.
17. Gilbert B, Yardin C, Briault S, Belin V, Lienhardt A, Aubard Y, Battin J, Servaud M, Philippe HJ & Lacombe D. Prenatal diagnosis of female monozygotic twins discordant for Turner syndrome: implications for prenatal genetic counselling. Prenatal Diagnosis 2002 22 697-702.
18. Andersen E, Sonnesen L, Kjaer MS, Fischer HB & Kjaer I. The prenatal cranial base complex and hand in Turner syndrome. European Journal of Orthodontics 2000 22 185-194.
19. Harting UB, Hansen BF, Keeling JW, Skovgaard LT & Kjaer I. Short bi-iliac distance in prenatal Ullrich-Turner syndrome. American Journal of Medical Genetics 2002 108 290-294.
20. Stoll C, Garne E & Clementi M. Evaluation of prenatal diagnosis of associated congenital heart diseases by fetal ultrasonographic examination in Europe. Prenatal Diagnosis 2001 21 243-252.
21. Huggon IC, Ghi T, Cook AC, Zosmer N, Allan LD & Nicolaides KH. Fetal cardiac abnormalities identified prior to 14 weeks' gestation. Ultrasound in Obstetrics & Gynecology 2002 20 22-29.
22. Baena N, De Vigan C, Cariati E, Clementi M, Stoll C, Caballin MR & Guitart M. Turner syndrome: evaluation of prenatal diagnosis in 19 European registries. American Journal of Medical Genetics 2004 129A 16-20.
23. Mansfield C, Hopfer S & Marteau TM. Termination rates after prenatal diagnosis of Down syndrome, spina bifida, anencephaly, and Turner and Klinefelter syndromes: a systematic literature review. European Concerted Action: DADA (Decision-making After the Diagnosis of a fetal Abnormality). Prenatal Diagnosis 1999 19 808-812.
24. Christian SM, Koehn D, Pillay R, MacDougall A & Wilson RD. Parental decisions following prenatal diagnosis of sex chromosome aneuploidy: a trend over time. Prenatal Diagnosis 2000 20 37-40.
25. Jacobs PA, Melville M, Ratcliffe S, Keay AJ & Syme J. A cytogenetic survey of 11 680 newborn infants. Annals of Human Genetics 1974 37 359-376.
26. Nielsen J & Wohlert M. Chromosome abnormalities found among 34910 newborn children: results from a 13-year incidence study in Aarhus, Denmark. Human Genetics 1991 87 81-83.
27. Imaizumi K & Kuroki Y. Prevalence of Turner syndrome in Japan. In Basic and Clinical Approach to Turner Syndrome, pp 3-6. Eds I Hibi & K Takano. Amsterdam: Excerpta Medica, 1993.
28. Savendahl L & Davenport ML. Delayed diagnoses of Turner's syndrome: proposed guidelines for change. Journal of Pediatrics 2000 137 455-459.
29. Hasle H, Olsen JH, Nielsen J, Hansen J, Friedrich U & Tommerup N. Occurrence of cancer in women with Turner syndrome. British Journal of Cancer 1996 73 1156-1159.
30. Women's Health Initiative. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. Journal of the American Medical Association 2002 288 321-333.
31. Swerdlow AJ, Hermon C, Jacobs PA, Alberman E, Beral V, Daker M, Fordyce A & Youings S. Mortality and cancer incidence in persons with numerical sex chromosome abnormalities: a cohort study. Annals of Human Genetics 2001 65 177-188.
32. Price WH, Clayton JE Collyer S, De Mey R & Wilson J. Mortality ratios, life expectancy, and causes of death in patients with Turner's syndrome. Journal of Epidemiology and Community Health 1986 40 97-102.
33. Singh RP & Carr DH. The anatomy and histology of XO human embryos and fetuses. Anatomical Record 1966 155 369-383.
34. Carr DH, Haggar RA & Hart AG. Germ cells in the ovaries of XO female infants. American Journal of Clinical Pathology 1968 49 521-526.
35. Speed RM. Oocyte development in XO foetuses of man and mouse: the possible role of heterologous X-chromosome pairing in germ cell survival. Chromosoma 1986 94 115-124.
36. Conte FA, Grumbach MM & Kaplan SL. A diphasic pattern of gonadotropin secretion in patients with the syndrome of gonadal dysgenesis. Journal of Clinical Endocrinology and Metabolism 1975 40 670-674.
37. Heinrichs C, Bourdoux P, Saussez C, Vis HL & Bourguignon JP. Blood spot follicle-stimulating hormone during early postnatal life in normal girls and Turner's syndrome. Journal of Clinical Endocrinology and Metabolism 1994 78 978-981.
38. Nathwani NC, Hindmarsh PC, Massarano AA & Brook CG. Gonadotrophin pulsatility in girls with the Turner syndrome: modulation by exogenous sex steroids. Clinical Endocrinology 1998 49 107-113.
39. Hreinsson JG, Otala M, Fridstrom M, Borgstrom B, Rasmussen C, Lundqvist M, Tuuri T, Simberg N, Mikkola M, Dunkel L & Hovatta O. Follicles are found in the ovaries of adolescent girls with Turner's syndrome. Journal of Clinical Endocrinology and Metabolism 2002 87 3618-3623.
40. Gravholt CH, Naeraa RW, Andersson AM, Christiansen JS & Skakkebaek NE. Inhibin A and B in adolescents and young adults with Turner's syndrome and no sign of spontaneous puberty. Human Reproduction 2002 17 2049-2053.
41. Groome NP, Illingworth PJ, O'Brien M, Pai R, Rodger FE, Mather JP & McNeilly AS. Measurement of dimeric inhibin B throughout the human menstrual cycle. Journal of Clinical Endocrinology and Metabolism 1996 81 1401-1405.
42. Sehested A, Juul AA, Andersson AM, Petersen JH, Jensen TK, Muller J & Skakkebaek NE. Serum inhibin A and inhibin B in healthy prepubertal, pubertal, and adolescent girls and adult women: relation to age, stage of puberty, menstrual cycle, follicle-stimulating hormone, luteinizing hormone, and estradiol levels. Journal of Clinical Endocrinology and Metabolism 2000 85 1634-1640.
43. Roberts VJ, Barth S, el-Roeiy A & Yen SS. Expression of inhibin/ activin system messenger ribonucleic acids and proteins in ovarian follicles from women with polycystic ovarian syndrome. Journal of Clinical Endocrinology and Metabolism 1994 79 1434-1439.
44. Muttukrishna S, Child TJ, Groome NP & Ledger WL. Source of circulating levels of inhibin A, pro alpha C-containing inhibins and activin A in early pregnancy. Human Reproduction 1997 12 1089-1093.
45. Pasquino AM, Passeri F, Pucarelli I, Segni M & Municchi G. Spontaneous pubertal development in Turner's syndrome. Italian Study Group for Turner's Syndrome. Journal of Clinical Endocrinology and Metabolism 1997 82 1810-1813.
46. Modi DN, Sane S & Bhartiya D. Accelerated germ cell apoptosis in sex chromosome aneuploid fetal human gonads. Molecular Human Reproduction 2003 9 219-225.
47. Reynaud K, Cortvrindt R, Verlinde F, De Schepper J, Bourgain C & Smitz J. Number of ovarian follicles in human fetuses with the 45,X karyotype. Fertility and Sterility 2004 81 1112-1119.
48. Boechat MI, Westra SJ & Lippe B. Normal US appearance of ovaries and uterus in four patients with Turner's syndrome and 45,X karyotype. Pediatric Radiology 1996 26 37-39.
49. Hovatta O. Pregnancies in women with Turner's syndrome. Annals of Medicine 1999 31 106-110.
50. Chernausek SD, Attie KM, Cara JF, Rosenfeld RG & Franc J. Growth hormone therapy of Turner syndrome: the impact of age of estrogen replacement on final height. Genentech, Inc., Collaborative Study Group. Journal of Clinical Endocrinology and Metabolism 2000 85 2439-2445.
51. Van Pareren YK, de Muinck Keizer-Schrama SM, Stijnen T, Sas TC, Jansen M, Otten BJ, Hoorweg-Nijman JJ, Vulsma T, Stokvis-Brantsma WH, Rouwe CW, Reeser HM, Gerver WJ, Gosen JJ, Rongen-Westerlaken C & Drop SL. Final height in girls with Turner syndrome after long-term growth hormone treatment in three dosages and low dose estrogens. Journal of Clinical Endocrinology and Metabolism 2003 88 1119-1125.
52. Massa G, Heinrichs C, Verlinde S, Thomas M, Bourguignon JP, Craen M, Francois I, Du CM, Maes M & De Schepper J. Late or delayed induced or spontaneous puberty in girls with Turner syndrome treated with growth hormone does not affect final height. Journal of Clinical Endocrinology and Metabolism 2003 88 4168-4174.
53. Ross JL, Roeltgen D, Feuillan P, Kushner H & Cutler GB Jr. Effects of estrogen on nonverbal processing speed and motor function in girls with Turner's syndrome. Journal of Clinical Endocrinology and Metabolism 1998 83 3198-3204.
54. Ross JL, Roeltgen D, Feuillan P, Kushner H & Cutler GB Jr. Use of estrogen in young girls with Turner syndrome: effects on memory. Neurology 2000 54 164-170.
55. Ross JL, Stefanatos GA, Kushner H, Zinn A, Bondy C & Roeltgen D. Persistent cognitive deficits in adult women with Turner syndrome. Neurology 2002 58 218-225.
56. Sylven L, Magnusson C, Hagenfeldt K & von Schoultz B. Life with Turner's syndrome - a psychosocial report from 22 middle-aged women. Acta Endocrinologica 1993 129 188-194.
57. Khastgir G, Abdalla H, Thomas A, Korea L, Latarche L & Studd J. Oocyte donation in Turner's syndrome: an analysis of the factors affecting the outcome. Human Reproduction 1997 12 279-285.
58. Foudila T, Soderstrom AV & Hovatta O. Turner's syndrome and pregnancies after oocyte donation. Human Reproduction 1999 14 532-535.
59. Yaron Y, Ochshorn Y, Amit A, Yovel I, Kogosowki A & Lessing JB. Patients with Turner's syndrome may have an inherent endometrial abnormality affecting receptivity in oocyte donation. Fertility and Sterility 1996 65 1249-1252.
60. Ranke MB, Pfluger H, Rosendahl W, Stubbe P, Enders H, Bierich JR & Majewski F. Turner syndrome: spontaneous growth in 150 cases and review of the literature. European Journal of Pediatrics 1983 141 81-88.
61. Sybert VP. Adult height in Turner syndrome with and without androgen therapy. Journal of Pediatrics 1984 104 365-369.
62. Lyon AJ, Preece MA & Grant DB. Growth curve for girls with Turner syndrome. Archives of Diseases in Childhood 1985 60 932-935.
63. Suwa S. Standards for growth and growth velocity in Turner's syndrome. Acta Paediatrica Japonica 1992 34 206-220.
64. Rochiccioli P, David M, Malpuech G, Colle M, Limal JM, Battin J, Mariani R, Sultan C, Nivelon JL, Simonin G, Bost M, Chatelain P, Bertrand AM, Freycon R, Bouquier JJ & Pierron P. Study of final height in Turner's syndrome: ethnic and genetic influences. Acta Paediatrica 1994 83 305-308.
65. Garcia Rudaz C, Martinez AS, Heinrich JJ, Lejarraga H, Keselman A, Laspiur M & Bergada C. Growth of Argentinian girls with Turner syndrome. Annals of Human Biology 1995 22 533-544.
66. Low LC, Sham C, Kwan E, Karlberg J, Tang G, Cheung PT, Pang H, Tse W, But B, Yu CM & Lam ST. Spontaneous growth in Chinese patients with Turner's syndrome and influence of karyotype. Acta Paediatrica 1997 86 18-21.
67. Rongen Westerlaken C, Corel L, Van den Broeck J, Massa G, Karlberg J, Albertsson Wikland K, Naeraa RW & Wit JM. Reference values for height, height velocity and weight in Turner's syndrome. Swedish Study Group for GH Treatment. Acta Paediatrica 1997 86 937-942.
68. Gravholt CH & Naeraa RW. Reference values for body proportions and body composition in adult women with Turner's syndrome. American Journal of Medical Genetics 1997 72 403-408.
69. Karlberg J, Albertsson WK, Nilsson KO, Ritzen EM & Westphal O. Growth in infancy and childhood in girls with Turner's syndrome. Acta Paediatrica Scandinavica 1991 80 1158-1165.
70. Davenport ML, Punyasavatsut N, Gunther D, Savendahl L & Stewart PW. Turner syndrome: a pattern of early growth failure. Acta Paediatrica 1999 88 (Suppl) 118-121.
71. Even L, Cohen A, Marbach N, Brand M, Kauli R, Sippell W & Hochberg Z. Longitudinal analysis of growth over the first 3 years of life in Turner's syndrome. Journal of Pediatrics 2000 137 460-464.
72. Rao E, Weiss B, Fukami M, Rump A, Niesler B, Mertz A, Muroya K, Binder G, Kirsch S, Winkelmann M, Nordsiek G, Heinrich U, Breuning MH, Ranke MB, Rosenthal A, Ogata T & Rappold GA. Pseudoautosomal deletions encompassing a novel homeobox gene cause growth failure in idiopathic short stature and Turner syndrome. Nature Genetics 1997 16 54-63.
73. Ellison JW, Wardak Z, Young W, Robey PG, Laig-Webster M & Chiong W. PHOG, a candidate gene for involvement in the short stature of Turner syndrome. Human Molecular Genetics 1997 6 1341-1347.
74. Clement-Jones M, Schiller S, Rao E, Blaschke RJ, Zuniga A, Zeller R, Robson SC, Binder G, Glass I, Strachan T, Lindsay S & Rappold GA. The short stature homeobox gene SHOX is involved in skeletal abnormalities in Turner syndrome. Hum Mol Genet 2000 9 695-702.
75. Ogata T, Matsuo N & Nishimura G. SHOX haploinsufficiency and overdosage: impact of gonadal function status. Journal of Medical Genetics 2001 38 1-6.
76. Gravholt CH, Lauridsen AL, Brixen K, Mosekilde L, Heickendorff L & Christiansen JS. Marked dysproportionality in bone size and mineral, and distinct abnormalities in bone markers and calcitropic hormones in adult Turner syndrome. A cross-sectional study. Journal of Clinical Endocrinology and Metabolism 2002 87 2798-2808.
77. Kosho T, Muroya K, Nagai T, Fujimoto M, Yokoya S, Sakamoto H, Hirano T, Terasaki H, Ohashi H, Nishimura G, Sato S, Matsuo N & Ogata T. Skeletal features and growth patterns in 14 patients with haploinsufficiency of SHOX: implications for the development of Turner syndrome. Journal of Clinical Endocrinology and Metabolism 1999 84 4613-4621.
78. Sas TC, Muinck Keizer-Schrama SM, Stijnen T, Jansen M, Otten BJ, Hoorweg-Nijman JJ, Vulsma T, Massa GG, Rouwe CW, Reeser HM, Gerver WJ, Gosen JJ, Rongen-Westerlaken C & Drop SL. Normalization of height in girls with Turner syndrome after long-term growth hormone treatment: results of a randomized dose-response trial. Journal of Clinical Endocrinology and Metabolism 1999 84 4607-4612.
79. Carel JC, Mathivon L, Gendrel C, Ducret JP & Chaussain JL. Near normalization of final height with adapted doses of growth hormone in Turner's syndrome. Journal of Clinical Endocrinology and Metabolism 1998 83 1462-1466.
80. Ross JL, Long LM, Loriaux DL & Cutler GBJ. Growth hormone secretory dynamics in Turner syndrome. Journal of Pediatrics 1985 106 202-206.
81. Lin TH, Kirkland JL & Kirkland RT. Growth hormone assessment and short-term treatment with growth hormone in Turner syndrome. Journal of Pediatrics 1988 112 919-922.
82. Massarano AA, Brook CG, Hindmarsh PC, Pringle PJ, Teale JD, Stanhope R & Preece MA. Growth hormone secretion in Turner's syndrome and influence of oxandrolone and ethinyl oestradiol. Archives of Diseases in Childhood 1989 64 587-592.
83. Reiter JC, Craen M & Van Vliet G. Decreased growth hormone response to growth hormone-releasing hormone in Turner's syndrome: relation to body weight and adiposity. Acta Endocrinologica 1991 125 38-42.
84. Zadik Z, Landau H, Chen M, Altman Y & Lieberman E. Assessment of growth hormone (GH) axis in Turner's syndrome using 24-hour integrated concentrations of GH, insulin-like growth factor-I, plasma GH-binding activity, GH binding to IM9 cells, and GH response to pharmacological stimulation. Journal of Clinical Endocrinology and Metabolism 1992 75 412-416.
85. Ranke MB, Blum WF, Haug F, Rosendahl W, Attanasio A, Enders H, Gupta D & Bierich JR. Growth hormone, somatomedin levels and growth regulation in Turner's syndrome. Acta Endocrinologica 1987 116 305-313.
86. Saenger P, Schwartz E, Wiedemann E, Levine LS, Tsai M & New MI. The interaction of growth hormone, somatomedin and oestrogen in patients with Turner's syndrome. Acta Endocrinologica 1976 81 9-18.
87. Wit JM, Massarano AA, Kamp GA, Hindmarsh PC, van Es A, Brook CG, Preece MA & Matthews DR. Growth hormone secretion in patients with Turner's syndrome as determined by time series analysis. Acta Endocrinologica 1992 127 7-12.
88. Lanes R, Brito S, Suniaga M, Moncada G & Borges M. Growth hormone secretion in pubertal age patients with Turner's syndrome. Journal of Clinical Endocrinology and Metabolism 1990 71 770-772.
89. Gravholt CH, Naeraa RW, Fisker S & Christiansen JS. Body composition and physical fitness are major determinants of the growth hormone-IGF axis aberrations in adult Turner syndrome, with important modulations by treatment with 17-beta-estradiol. Journal of Clinical Endocrinology and Metabolism 1997 82 2570-2577.
90. Foster CM, Borondy M, Markovs ME, Hopwood NJ, Kletter GB & Beitins IZ. Growth hormone bioactivity in girls with Turner's syndrome: correlation with insulin-like growth factor I. Pediatric Research 1994 35 218-222.
91. Blethen SL, Albertsson Wikland K, Faklis EJ & Chasalow FI. Circulating growth hormone isoforms in girls with Turner's syndrome. Journal of Clinical Endocrinology and Metabolism 1994 78 1439-1443.
92. Ishikawa M, Yokoya S, Tachibana K, Hasegawa Y, Yasuda T, Tokuhiro E, Hashimoto Y & Tanaka T. Serum levels of 20-kilodalton human growth hormone (GH) are parallel to those of 22-kilodalton human GH in normal and short children. Journal of Clinical Endocrinology and Metabolism 1999 84 98-104.
93. Kohno H & Honda S. Low urinary growth hormone values in patients with Turner's syndrome. Journal of Clinical Endocrinology and Metabolism 1992 74 619-622.
94. Ghizzoni L, Lamborghini A, Ziveri M, Volta C, Panza C, Balestrazzi P & Bernasconi S. Pulsatile growth hormone release in Turner's syndrome and short normal children. Acta Endocrinologica 1990 123 291-297.
95. Gravholt CH, Veldbuis JD & Christiansen JS. Increased disorderliness and decreased mass and daily rate of endogenous growth hormone secretion in adult Turner syndrome: the impact of body composition, maximal oxygen uptake and treatment with sex hormones. Growth Hormone IGF Res 1998 8 289-298.
96. Pincus SM, Gevers EF, Robinson IC, Van den Berg G, Roelfsema F, Hartman ML & Veldhuis JD. Females secrete growth hormone with more process irregularity than males in both humans and rats. American Journal of Physiology 1996 270 E107-E115.
97. Apter D, Lenko HL, Perheentupa J, Soderholm A & Vihko R. Sub-normal pubertal increases of serum androgens in Turner's syndrome. Hormone Research 1982 16 164-173.
98. Gravholt CH, Svenstrup B, Bennett P & Christiansen JS. Low androgen levels in adult Turner syndrome: influence of female sex hormones and growth hormone status. Clinical Endocrinology 1999 50 791-800.
99. Attie KM, Julius JR, Stoppani C & Rundle AC. National Cooperative Growth Study substudy VI: the clinical utility of growth-hormone-binding protein, insulin-like growth factor I, and insulin-like growth factor-binding protein 3 measurements. Journal of Pediatrics 1997 131 S56-S60.
100. Carlsson LM, Attie KM, Compton PG, Vitangcol RV & Merimee TJ. Reduced concentration of serum growth hormone-binding protein in children with idiopathic short stature. National Cooperative Growth Study. Journal of Clinical Endocrinology and Metabolism 1994 78 1325-1330.
101. Massa G, Bouillon R & Vanderschueren LM. Serum growth hormone (GH)-binding protein and insulin-like growth factor-I levels in Turner's syndrome before and during treatment with recombinant human GH and ethinyl estradiol. Journal of Clinical Endocrinology and Metabolism 1992 75 1298-1302.
102. Naeraa RW, Gravholt CH, Kastrup KW, Svenstrup B & Christiansen JS. Morning versus evening administration of estradiol to girls with Turner syndrome receiving growth hormone: impact on growth hormone and metabolism. A randomized placebo-controlled crossover study. Acta Paediatrica 2001 90 526-531.
103. Fisker S, Vahl N, Jorgensen JO, Christiansen JS & Orskov H. Abdominal fat determines growth hormone binding protein levels in healthy non-obese adults. Journal of Clinical Endocrinology and Metabolism 1997 82 123-128.
104. Daughaday WH & Rotwein P. Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations. Endocrine Reviews 1989 10 68-91.
105. Cuttler L, Van Vliet G, Conte FA, Kaplan SL & Grumbach MM. Somatomedin-C levels in children and adolescents with gonadal dysgenesis: differences from age-matched normal females and effect of chronic estrogen replacement therapy. Journal of Clinical Endocrinology and Metabolism 1985 60 1087-1092.
106. Ross JL, Cassorla FG, Skerda MC, Valk IM, Loriaux DL & Cutler GBJ. A preliminary study of the effect of estrogen dose on growth in Turner's syndrome. New England Journal of Medicine 1983 309 1104-1106.
107. Wiedemann E, Schwartz E & Frantz AG. Acute and chronic estrogen effects upon serum somatomedin activity, growth hormone, and prolactin in man. Journal of Clinical Endocrinology and Metabolism 1976 42 942-952.
108. Gravholt CH, Frystyk J, Flyvbjerg A, Orskov H & Christiansen JS. Reduced free IGF-I and increased IGFBP-3 proteolysis in Turner syndrome: modulation by female sex steroids. American Journal of Physiology 2001 280 E308-E314.
109. Westwood M, Gibson JM, Williams AC, Clayton PE, Hamberg O, Flyvbjerg A & White A. Hormonal regulation of circulating insulin-like growth factor-binding protein-1 phosphorylation status. Journal of Clinical Endocrinology and Metabolism 1995 80 3520-3527.
110. Westwood M, Gibson JM, Pennells LA & White A. Modification of plasma insulin-like growth factors and binding proteins during oral contraceptive use and the normal menstrual cycle. American Journal of Obstetrics and Gynecology 1999 180 530-536.
111. Frystyk J, Hojlund K, Rasmussen KN, Jorgensen SP, Wildner-Christensen M & Orskov H. Development and clinical evaluation of a novel immunoassay for the binary complex of IGF-I and IGF-binding protein 1 in human serum. Journal of Clinical Endocrinology and Metabolism 2002 87 260-266.
112. Cox GN, McDermott MJ, Merkel E, Stroh CA, Ko SC, Squires CH, Gleason TM & Russell D. Recombinant human insulin-like growth factor (IGF)-binding protein-1 inhibits somatic growth stimulated by IGF-I and growth hormone in hypophysectomized rats. Endocrinology 1994 135 1913-1920.
113. Baxter RC. Insulin-like growth factor (IGF)-binding proteins: interactions with IGFs and intrinsic bioactivities. American Journal of Physiology, Endocrinology and Metabolism 2000 278 E967-E976.
114. Hochberg Z, Aviram M, Rubin D & Pollack S. Decreased sensitivity to insulin-like growth factor I in Turner's syndrome: a study of monocytes and T lymphocytes. European Journal of Clinical Investigation 1997 27 543-547.
115. Rosenfeld RG, Hintz RL, Johanson AJ, Brasel JA, Burstein S, Chernausek SD, Clabots T, Frane J, Gotlin RW & Kuntze J. Methionyl human growth hormone and oxandrolone in Turner syndrome: preliminary results of a prospective randomized trial. Journal of Pediatrics 1986 109 936-943.
116. Rongen-Westerlaken C, Wit JM, Drop SL, Often BJ, Oostdijk W, Waal HA, Gons MH, Bot A & Van den Brande JL. Methionyl human growth hormone in Turner's syndrome. Archives of Diseases in Childhood 1988 63 1211-1217.
117. Takano K, Hizuka N & Shizume K. Treatment of Turner's syndrome with methionyl human growth hormone for six months. Acta Endocrinologica 1986 112 130-137.
118. Vanderschueren LM, Massa G, Maes M, Craen M, Van Vliet G, Heinrichs C & Malvaux P. Growth-promoting effect of growth hormone and low dose ethinyl estradiol in girls with Turner's syndrome. Journal of Clinical Endocrinology and Metabolism 1990 70 122-126.
119. Knudtzon J & Aarskog D. Results of two years of growth hormone treatment followed by combined growth hormone and oestradiol in Turner syndrome. The Norwegian Turner Study Group. Hormone Research 1993 39 (Suppl 2) 7-17.
120. Lenko HL, Hakulinen A, Kaar ML, Maenpaa J, Makela AL & Sipila I. Effect of conventional dose growth hormone therapy for two years on height velocity and height prognosis in girls with Turner syndrome. Hormone Research 1993 39 (Suppl 2) 3-6.
121. Rochiccioli P, Battin J, Bertrand AM, Bost M, Cabrol S, Le Bouc Y, Chaussain JL, Chatelain P, Colle M & Czernichow P. Final height in Turner syndrome patients treated with growth hormone. Hormone Research 1995 44 172-176.
122. Van den Broeck J, Massa GG, Attanasio A, Matranga A, Chaussain JL, Price DA, Aarskog D & Wit JM. Final height after long-term growth hormone treatment in Turner syndrome. European Study Group. Journal of Pediatrics 1995 127 729-735.
123. Dacou VC, Karavanaki KK, Petrou V, Georgopoulos N, Maniati CM & Mavrou A. The growth pattern and final height of girls with Turner syndrome with and without human growth hormone treatment. Pediatrics 1998 101 663-668.
124. Pasquino AM, Passeri F, Municchi G, Segni M, Pucarelli I, Larizza D, Bossi G, Severi F & Galasso C. Final height in Turner syndrome patients treated with growth hormone. Hormone Research 1996 46 269-272.
125. Taback SP, Collu R, Deal CL, Guyda HJ, Salisbury S, Dean HJ & Van Vliet G. Does growth-hormone supplementation affect adult height in Turner's syndrome? Lancet 1996 348 25-27.
126. Takano K, Ogawa M, Tanaka T, Tachibana K, Fujita K & Hizuka N. Clinical trials of GH treatment in patients with Turner's syndrome in Japan - a consideration of final height. The Committee for the Treatment of Turner's Syndrome. European Journal of Endocrinology 1997 137 138-145.
127. Chu CE, Paterson WF, Kelnar CJ, Smail PJ, Greene SA & Donaldson MD. Variable effect of growth hormone on growth and final adult height in Scottish patients with Turner's syndrome. Acta Paediatrica 1997 86 160-164.
128. Hochberg Z & Zadik Z. Final height in young women with Turner syndrome after GH therapy: an open controlled study. European Journal of Endocrinology 1999 141 218-224.
129. Cacciari E & Mazzanti L. Final height of patients with Turner's syndrome treated with growth hormone (GH): indications for GH therapy alone at high doses and late estrogen therapy. Italian Study Group for Turner Syndrome. Journal of Clinical Endocrinology and Metabolism 1999 84 4510-4515.
130. Ranke MB, Partsch CJ, Lindberg A, Dorr HG, Bettendorf M, Hauffa BP, Schwarz HP, Mehls O, Sander S, Stahnke N, Steinkamp H, Said E & Sippell W. Adult height after GH therapy in 188 Ullrich-Turner syndrome patients: results of the German IGLU Follow-up Study 2001. European Journal of Endocrinology 2002 147 625-633.
131. Quigley CA, Crowe BJ, Anglin DG & Chipman JJ. Growth hormone and low dose estrogen in Turner syndrome: results of a United States multi-center trial to near-final height. Journal of Clinical Endocrinology and Metabolism 2002 87 2033-2041.
132. Rosenbloom AL & Frias JL. Oxandrolone for growth promotion in Turner syndrome. American Journal of Diseases in Children 1973 125 385-387.
133. Moore DC, Tattoni DS, Ruvalcaba RH, Limbeck GA & Kelley VC. Studies of anabolic steroids. VI. Effect of prolonged administration of oxandrolone on growth in children and adolescents with gonadal dysgenesis. Journal of Pediatrics 1977 90 462-466.
134. Rudman D, Goldsmith M, Kutner M & Blackston D. Effect of growth hormone and oxandrolone singly and together on growth rate in girls with X chromosome abnormalities. Journal of Pediatrics 1980 96 132-135.
135. Haeusler G, Schmitt K, Blumel P, Plochl E, Waldhor T & Frisch H. Growth hormone in combination with anabolic steroids in patients with Turner syndrome: effect on bone maturation an final height. Acta Paediatrica 1996 85 1408-1414.
136. Nilsson KO, Albertsson Wikland K, Alm J, Aronson S, Gustafsson J, Hagenas L, Hager A, Ivarsson SA, Karlberg J, Kristrom B, Marcus C, Moell C, Ritzen M, Tuvemo T, Wattsgard C, Westgren U, Westphal O & Aman J. Improved firial height in girls with Turner's syndrome treated with growth hormone and oxandrolone. Journal of Clinical Endocrinology and Metabolism 1996 81 635-640.
137. Rosenfeld RG, Attie KM, Frane J, Brasel JA, Burstein S, Cara JF, Chernausek S, Gotlin RW, Kuntze J, Lippe BM, Mahoney CP, Moore WV, Saenger P & Johanson AJ. Growth hormone therapy of Turner's syndrome: beneficial effect on adult height. Journal of Pediatrics 1998 132 319-324.
138. Stahnke N, Keller E & Landy H. Favorable final height outcome in girls with Ullrich-Turner syndrome treated with low-dose growth hormone together with oxandrolone despite starting treatment after 10 years of age. J Pediatr Endocrinol Metab 2002 15 129-138.
139. Neely EK, Marcus R, Rosenfeld RG & Bachrach LK. Turner syndrome adolescents receiving growth hormone are not osteopenic. Journal of Clinical Endocrinology and Metabolism 1993 76 861-866.
140. Lanes R, Gunczler P, Paoli M & Weisinger JR. Bone mineral density of prepubertal age girls with Turner's syndrome while on growth hormone therapy. Hormone Research 1995 44 168-171.
141. Bergmann P, Valsamis J, Van Perborgh J, De Schepper J & Van Vliet G. Comparative study of the changes in insulin-like growth factor-I, procollagen-III N-terminal extension peptide, bone Gla-protein, and bone mineral content in children with Turner's syndrome treated with recombinant growth hormone. Journal of Clinical Endocrinology and Metabolism 1990 71 1461-1467.
142. Gravholt CH, Naeraa RW, Brixen K, Kastrup KW. Mosekilde L, Jørgensen JO & Christiansen JS. Short term growth hormone treatment in girls with Turner syndrome decreases fat mass and insulin sensitivity. A randomized double-blind, placebo-controlled cross-over study. Pediatrics 2002 110 889-896.
143. Sas TC, Muinck Keizer-Schrama SM, Stijnen T, Asarfi A, Van Leeuwen WJ, van Teunenbroek A, Van Rijn RR & Drop SL. A longitudinal study on bone mineral density until adulthood in girls with Turner's syndrome participating in a growth hormone injection frequency-response
144. Lanes R, Gunczler P, Esaa S, Martinis R, Villaroel O & Weisinger JR. Decreased bone mass despite long-term estrogen replacement therapy in young women with Turner's syndrome and previously normal bone density. Fertility and Sterility 1999 72 896-899.
145. Bertelloni S, Cinquanta L, Baroncelli GI, Simi P, Rossi S & Saggese G. Volumetric bone mineral density in young women with Turner's syndrome treated with estrogens or estrogens plus growth hormone. Hormone Research 2000 53 72-76.
146. Sas TC, de Muinck Keizer-Schrama SM, Stijnen T, van Teunenbroek A, Van Leeuwen WJ, Asarfi A, Van Rijn RR & Drop SL. Bone mineral density assessed by phalangeal radiographic absorptiometry before and during long-term growth hormone treatment in girls with Turner's syndrome participating in a randomized dose-response study. Pediatric Research 2001 50 417-422.
147. Kastrup KW. Growth and development in girls with Turner's syndrome during early therapy with low doses of estradiol. Acta Endocrinologica 1986 279 (Suppl) 157-163.
148. Ranke MB, Haug F, Blum WF, Rosendahl W, Attanasio A & Bierich JR. Effect on growth of patients with Turner's syndrome treated with low estrogen doses. Acta Endocrinologica 1986 279 (Suppl) 153-156.
149. Bareille P, Massarano AA & Stanhope R. Final height outcome in girls with Turner syndrome treated with a combination of low dose oestrogen and oxandrolone. European Journal of Pediatrics 1997 156 358-362.
150. Lin TH, Kirkland RT & Kirkland JL. Adult height in girls with Turner syndrome treated with low-dose estrogens and androgens. Annals of Pharmacotherapy 1994 28 570-571.
151. Joss E & Zuppinger K. Oxandrolone in girls with Turner's syndrome. A pair-matched controlled study up to final height. Acta Peadiatrica Scandinavica 1984 73 674-679.
152. Naeraa RW, Nielsen J, Pedersen IL & Sorensen K. Effect of oxandrolone on growth and final height in Turner's syndrome. Acta Paediatrica Scandinavica 1990 79 784-789.
153. Crock P, Werther GA & Wettenhall HN. Oxandrolone increases final height in Turner syndrome. J Paediatr Child Health 1990 26 221-224.
154. Haeusler G & Frisch H. Growth hormone treatment in Turner's syndrome: short- and long-term effects on metabolic parameters. Clinical Endocrinology 1992 36 247-253.
155. Rudman D, Moffitt SD, Fernhoff PM, McKenzie WJ, Kenny JM & Bain RP. The relation between growth velocity and serum somatomedin C concentration. Journal of Clinical Endocrinology and Metabolism 1981 52 622-627.
156. Haeusler G, Frisch H, Schmitt K, Blumel P, Plochl E, Zachmann M & Waldhor T. Treatment of patients with Ullrich-Turner syndrome with conventional doses of growth hormone and the combination with testosterone or oxandrolone: effect on growth, IGF-I and IGFBP-3 concentrations. European Journal of Pediatrics 1995 154 437-444.
157. Haeusler G, Schmitt K, Blumel P, Plochl E, Waldhor T & Frisch H. Insulin, insulin-like growth factor-binding protein-1, and sex hormone-binding globulin in patients with Turner's syndrome: course over age in untreated patients and effect of therapy with growth hormone alone and in combination with oxandrolone. Journal of Clinical Endocrinology and Metabolism 1996 81 536-541.
158. Massa G, de Zegher F & Vanderschueren LM. Effect of growth hormone therapy on thyroid status of girls with Turner's syndrome. Clinical Endocrinology 1991 34 205-209.
159. Jorgensen JO, Moller J, Laursen T, Orskov H, Christiansen JS & Weeke J. Growth hormone administration stimulates energy expenditure and extrathyroidal conversion of thyroxine to triiodothyronine in a dose-dependent manner and suppresses circadian thyrotrophin levels: studies in GH-deficient adults. Clinical Endocrinology 1994 41 609-614.
160. Rother K, Zachmann M, Kempken B, Gruters A, Schnabel D, L'Allemand D, Hausler G & Frisch H. Effect of recombinant human growth hormone on urinary 15N-nitrogen balance in girls with Turner syndrome as compared to children with growth hormone deficiency. Hormone Research 1989 32 166-169.
161. Caprio S, Boulware SD, Press M, Sherwin RS, Rubin K, Carpenter TO, Plewe G & Tamborlane WV. Effect of growth hormone treatment on hyperinsulinemia associated with Turner syndrome. Journal of Pediatrics 1992 120 238-243.
162. Stoppoloni G, Prisco F, Alfano C, Iafusco D, Marrazzo G & Paolisso G. Characteristics of insulin resistance in Turner syndrome. Diabetes and Metabolism 1990 16 267-271.
163. Matsuda M & DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999 22 1462-1470.
164. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF & Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985 28 412-419.
165. Weise M, James D, Leitner CH, Hartmann KK, Bohles HJ & Attanasio A. Glucose metabolism in Ullrich Turner syndrome: long-term effects of therapy with human growth hormone. German Lilly UTS Study Group. Hormone Research 1993 39 36-41.
166. Sas TC, Muinck Keizer-Schrama SM, Stijnen T, Aanstoot HJ & Drop SL. Carbohydrate metabolism during long-term growth hormone (GH) treatment and after discontinuation of GH treatment in girls with Turner syndrome participating in a randomized dose-response study. Dutch Advisory Group on Growth Hormone. Journal of Clinical Endocrinology and Metabolism 2000 85 769-775.
167. Wilson DM, Frane JW, Sherman B, Johanson AJ, Hintz RL & Rosenfeld RG. Carbohydrate and lipid metabolism in Turner syndrome: effect of therapy with growth hormone, oxandrolone, and a combination of both. Journal of Pediatrics 1988 112 210-217.
168. Swearingen B, Barker FG, Katznelson L, Biller BM, Grinspoon S, Klibanski A, Moayeri N, Black PM & Zervas NT. Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly. Journal of Clinical Endocrinology and Metabolism 1998 83 3419-3426.
169. Gravholt CH. Turner syndrome and the heart: cardiovascular complications and treatment strategies. American Journal of Cardiovascular Drugs 2002 2 401-413.
170. Sas TC, Cromme-Dijkhuis AH, de Muinck K, Stijnen T, van Teunenbrock A & Drop SL. The effects of long-term growth hormone treatment on cardiac left ventricular dimensions and blood pressure in girls with Turner's syndrome. Journal of Pediatrics 1999 135 470-476.
171. Nathwani NC, Unwin R, Brook CG & Hindmarsh PC. The influence of renal and cardiovascular abnormalities on blood pressure in Turner syndrome. Clinical Endocrinology 2000 52 371-377.
172. Nathwani NC, Unwin R, Brook CG & Hindmarsh PC. Blood pressure and Turner syndrome. Clinical Endocrinology 2000 52 363-370.
173. Radetti G, Crepaz R, Milanesi O, Paganini C, Cesare, A, Rigon F & Pitscheider W. Cardiac performance in Turner's syndrome patients on growth hormone therapy. Hormone Research 2001 55 240-244.
174. Ross JL, Kushner H & Roeltgen DP. Developmental changes in motor function in girls with Turner syndrome. Pediatric Neurology 1996 15 317-322.
175. Bender BG, Linden MG & Robinson A. Neuropsychological impairment in 42 adolescents with sex chromosome abnormalities. American Journal of Medical Genetics 1993 48 169-173.
176. Rovet JF. The psychoeducational characteristics of children with Turner syndrome. Journal of Learning Disabilities 1993 26 333-341.
177. Ross JL, Stefanatos G, Roeltgen D, Kushner H & Cutler GB. Ullrich-Turner syndrome: neurodevelopmental changes from childhood through adolescence. American Journal of Medical Genetics 1995 58 74-82.
178. Ross JL, Stefanatos GA, Kushner H, Bondy C, Nelson L, Zinn A & Roeltgen D. The effect of genetic differences and ovarian failure: intact cognitive function in adult women with premature ovarian failure versus Turner syndrome. Journal of Clinical Endocrinology and Metabolism 2004 89 1817-1822.
179. Ross JL, Feuillan P, Kushner H, Roeltgen D & Cutler GB Jr. Absence of growth hormone effects on cognitive function in girls with Turner syndrome. Journal of Clinical Endocrinology and Metabolism 1997 82 1814-1817.
180. Rovet J & Holland J. Psychological aspects of the Canadian randomized controlled trial of human growth hormone and low-dose ethinyl oestradiol in children with Turner syndrome. The Canadian Growth Hormone Advisory Group. Hormone Research 1993 39 (Suppl 2) 60-64.
181. Ross JL, Roeltgen D, Stefanatos GA, Feuillan P, Kushner H, Bondy C & Cutler JG Jr. Androgen-responsive aspects of cognition in girls with Turner syndrome. Journal of Clinical Endocrinology and Metabolism 2003 88 292-296.
182. Bryant J, Cave C, Mihaylova B, Chase D, McIntyre L, Gerard K & Milne R. Clinical effectiveness and cost-effectiveness of growth hormone in children: a systematic review and economic evaluation. Health Technology Assessment 2002 6 1-168.
183. Caprio S, Boulware S, Diamond M, Sherwin RS, Carpenter TO, Rubin K, Amiel S, Press M & Tamborlane WV. Insulin resistance: an early metabolic defect of Turner's syndrome. Journal of Clinical Endocrinology and Metabolism 1991 72 832-836.
184. Cicognani A, Mazzanti L, Tassinari D, Pellacani A, Forabosco A, Landi L, Pifferi C & Cacciari E. Differences in carbohydrate tolerance in Turner syndrome depending on age and karyotype. European Journal of Pediatrics 1988 148 64-68.
185. Nielsen J, Johansen K & Yde H. The frequency of diabetes mellitus in patients with Turner's syndrome and pure gonadal dysgenesis. Blood glucose, plasma insulin and growth hormone level during an oral glucose tolerance test. Acta Endocrinologica 1969 62 251-269.
186. Rasio E, Antaki A & Van Campenhout J. Diabetes mellitus in gonadal dysgenesis: studies of insulin and growth hormone secretion. European Journal of Clinical Investigation 1976 6 59-66.
187. Holl RW, Kunze D, Etzrodt H, Teller W & Heinze E. Turner syndrome: final height, glucose tolerance, bone density and psychosocial status in 25 adult patients. European Journal of Pediatrics 1994 153 11-16.
188. Gravholt CH, Naeraa RW, Nyholm B, Gerdes U, Christiansen E, Schmitz O & Christiansen JS. Glucose metabolism, lipid metabolism, and cardiovascular risk factors in adult Turner syndrome: the impact of sex hormone replacement. Diabetes Care 1998 21 1062-1070.
189. Cobelli C, Caumo A & Omenetto M. Minimal model S(G) overestimation and S(I) underestimation: improved accuracy by a Bayesian two-compartment model. American Journal of Physiology 1999 277 E481-E488.
190. Landin-Wilhelmsen K, Bryman I & Wilhelmsen L. Cardiac malformations and hypertension, but not metabolic risk factors, are common in Turner syndrome. Journal of Clinical Endocrinology and Metabolism 2001 86 4166-4170.
191. Coutinho M, Gerstein HC, Wang Y & Yusuf S. The relationship between glucose and incident cardiovascular events. A metaregression. analysis of published data from 20 studies of 95 783 individuals followed for 12.4 years. Diabetes Care 1999 22 233-240.
192. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Europe. Lancet 1999 354 617-621.
193. Gravholt CH, Nyholm B, Saltin B, Schmitz O & Christiansen JS. Muscle fiber composition and capillary density in Turner syndrome: evidence of increased muscle fiber size related to insulin resistance. Diabetes Care 2001 24 1668-1673.
194. Randle PJ, Garland PB, Hales CN & Newsholme EA. The glucose fatty-acid cycle. Its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963 1 785-789.
195. Forbes AP & Engel E. The high incidence of diabetes mellitus in 41 patients with gonadal dysgenesis, and their close relatives. Metabolism 1963 12 428-439.
196. Polychronakos C, Letarte J, Collu R & Ducharme JR. Carbohydrate intolerance in children and adolescents with Turner syndrome. Journal of Pediatrics 1980 96 1009-1014.
197. Costin G & Kogut MD. Carbohydrate intolerance in gonadal dysgenesis: evidence for insulin resistance and hyperglucagonemia. Hormone Research 1985 22 260-269.
198. Cagnacci A, Soldani R, Carriero PL, Paoletti AM, Fioretti P & Melis GB. Effects of low doses of transdermal 17 beta-estradiol on carbohydrate metabolism in postmenopausal women. Journal of Clinical Endocrinology and Metabolism 1992 74 1396-1400.
199. Stevenson JC, Crook D, Godsland IF, Lees B & Whitehead MI. Oral versus transdermal hormone replacement therapy. International Journal of Fertility and Menopausal Studies 1993 38 (Suppl 1) 30-35.
200. Duncan AC, Lyall H, Roberts RN, Petrie JR, Perera MJ, Monaghan S, Hart DM, Connell JM & Lumsden MA. The effect of estradiol and a combined estradiol/progestagen preparation on insulin sensitivity in healthy postmenopausal women. Journal of Clinical Endocrinology and Metabolism 1999 84 2402-2407.
201. Luotola H, Pyorala T & Loikkanen M. Effects of natural oestrogen/progestogen substitution therapy on carbohydrate and lipid metabolism in post-menopausal women. Maturitas 1986 8 245-253.
202. Tonstad S, Ose L, Gorbitz C, Djoseland O, Bard JM & Fruchart JC. Efficacy of sequential hormone replacement therapy in the treatment of hypercholesterolaemia among postmenopausal women. Journal of Internal Medicine 1995 238 39-47.
203. Ryan AS, Nicklas BJ & Berman DM. Hormone replacement therapy, insulin sensitivity, and abdominal obesity in postmenopausal women. Diabetes Care 2002 25 127-133.
204. Munoz J, Derstine A & Gower BA. Fat distribution and insulin sensitivity in postmenopausal women: influence of hormone replacement. Obesity Research 2002 10 424-431.
205. Spencer CP, Godsland IF, Cooper AJ, Ross D, Whitehead MI & Stevenson JC. Effects of oral and transdermal 17beta-estradiol with cyclical oral norethindrone acetate on insulin sensitivity, secretion, and elimination in postmenopausal women. Metabolism 2000 49 742-747.
206. Elkind-Hirsch KE, Sherman LD & Malinak R. Hormone replacement therapy alters insulin sensitivity in young women with premature ovarian failure. Journal of Clinical Endocrinology and Metabolism 1993 76 472-475.
207. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B & Vittinghoff E. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. Journal of the American Medical Association 1998 280 605-613.
208. Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S & Horwitz RI. A clinical trial of estrogen-replacement therapy after ischemic stroke. New England Journal of Medicine 2001 345 1243-1249.
209. Bailey CJ & Ahmed Sorour H. Role of ovarian hormones in the long-term control of glucose homeostasis. Effects of insulin secretion. Diabetologia 1980 19 475-481.
210. Kumagai S, Holmang A & Bjorntorp P. The effects of oestrogen and progesterone on insulin sensitivity in female rats. Acta Physiologica Scandinavica 1993 149 91-97.
211. Berntorp K, Eriksson KF & Lindgarde F. The importance of diabetes heredity in lean subjects on insulin secretion, blood lipids and oxygen uptake in the pathogenesis of glucose intolerance. Diabetes Research 1986 3 231-236.
212. Berntorp K & Lindgarde F. Impaired physical fitness and insulin secretion in normoglycaemic subjects with familial aggregation of type 2 diabetes mellitus. Diabetes Research 1985 2 151-156.
213. Nyholm B, Mengel A, Nielsen S, Skjaerback C, Moller N, Alberti KGMM & Schmitz O. Insulin resistance in relatives of NIDDM patients: the role of physical fitness and muscle metabolism. Diabetologia 1996 39 813-822.
214. Beck Nielsen H & Groop LC. Metabolic and genetic characterization of prediabetic states. Sequence of events leading to non-insulin-dependent diabetes mellitus. Journal of Clinical Investigation 1994 94 1714-1721.
215. Marin P, Andersson B, Krotkiewski M & Bjorntorp P. Muscle fiber composition and capillary density in women and men with NIDDM. Diabetes Care 1994 17 382-386.
216. Saltin B & Strange S. Maximal oxygen uptake: 'old' and 'new' arguments for a cardiovascular limitation. Medicine and Science in Sports Exercise 1992 24 30-37.
217. Barr M Jr & Oman-Ganes L. Turner syndrome morphology and morphometrics: cardiac hypoplasia as a cause of midgestation death. Teratology 2002 66 65-72.
218. Rutherford OM & Jones DA. The relationship of muscle and bone loss and activity levels with age in women. Age and Ageing 1992 21 286-293.
219. Phillips SK, Rook KM, Siddle NC, Bruce SA & Woledge RC. Muscle weakness in women occurs at an earlier age than in men, but strength is preserved by hormone replacement therapy. Clinical Science 1993 84 95-98.
220. Sipila S, Taaffe DR, Cheng S, Puolakka J, Toivanen J & Suominen H. Effects of hormone replacement therapy and high-impact physical exercise on skeletal muscle in post-menopausal women: a randomized placebo-controlled study. Clinical Science 2001 101 147-157.
221. Pelz L, Sager G, Hinkel GK, Kirchner M, Kruger G & Verron G. Delayed spontaneous pubertal growth spurt in girls with the Ullrich-Turner syndrome. American Journal of Medical Genetics 1991 40 401-405.
222. Park E, Bailey JD & Cowell CA. Growth and maturation of patients with Turner's syndrome. Pediatric Research 1983 17 1-7.
223. Park E. Body shape in Turner's syndrome. Human Biology 1977 49 215-223.
224. Varrela J, Vinkka H & Alvesalo L. The phenotype of 45,X females: an anthropometric quantification. Annals of Human Biology 1984 11 53-66.
225. Leger J, Carel C, Legrand I, Paulsen A, Hassan M & Czernichow P. Magnetic resonance imaging evaluation of adipose tissue and muscle tissue mass in children with growth hormone (GH) deficiency, Turner's syndrome, and intrauterine growth retardation during the first year of treatment with GH. Journal of Clinical Endocrinology and Metabolism 1994 78 904-909.
226. Jorgensen JO, Vahl N, Hansen TB, Thuesen L, Hagen C & Christiansen JS. Growth hormone versus placebo treatment for one year in growth hormone deficient adults: increase in exercise capacity and normalization of body composition. Clinical Endocrinology 1996 45 681-688.
227. Sas T, Mulder P & Hokken-Koelega A. Body composition, blood pressure, and lipid metabolism before and during long-term growth hormone (GH) treatment in children with short stature born small for gestational age either with or without GH deficiency. Journal of Clinical Endocrinology and Metabolism 2000 85 3786-3792.
228. Sas TC, Gerver WJ, De Bruin R, Stijnen T, Muinck Keizer-Schrama SM, Cole TJ, van Teunenbroek A & Drop SL. Body proportions during long-term growth hormone treatment in girls with Turner syndrome participating in a randomized dose-response trial. Journal of Clinical Endocrinology and Metabolism 1999 84 4622-4628.
229. Van Pareren YK, de Muinck Keizer-Schrama SM, Stijnen T, Sas TC & Drop SL. Effect of discontinuation of long-term growth hormone treatment on carbohydrate metabolism and risk factors for cardiovascular disease in girls with Turner syndrome. Journal of Clinical Endocrinology and Metabolism 2002 87 5442-5448.
230. Burger HG, Dudley EC, Hopper JL, Shelley JM, Green A, Smith A, Dennerstein L & Morse C. The endocrinology of the menopausal transition: a cross-sectional study of a population-based sample. Journal of Clinical Endocrinology and Metabolism 1995 80 3537-3545.
231. Jensen J, Christiansen C & Rodbro P. Oestrogen-progestogen replacement therapy changes body composition in early postmenopausal women. Maturitas 1986 8 209-216.
232. Rebuffe Scrive M, Lonnroth P, Marin P, Wesslau C, Bjorntorp P & Smith U. Regional adipose tissue metabolism in men and postmenopausal women. International Journal of Obesity 1987 11 347-355.
233. Haarbo J, Marslew U, Gotfredsen A & Christiansen C. Postmenopausal hormone replacement therapy prevents central distribution of body fat after menopause. Metabolism 1991 40 1323-1326.
234. Gambacciani M, Ciaponi M, Cappagli B, Piaggesi L, De Simone L, Orlandi R & Genazzani AR. Body weight, body fat distribution, and hormonal replacement therapy in early postmenopausal women. Journal of Clinical Endocrinology and Metabolism 1997 82 414-417.
235. Rebuffe Scrive M, Eldh J, Hafstrom LO & Bjorntorp P. Metabolism of mammary, abdominal, and femoral adipocytes in women before and after menopause. Metabolism 1986 35 792-797.
236. Dallongeville J, Marecaux N, Isorez D, Zylbergberg G, Fruchart JC & Amouyel P. Multiple coronary heart disease risk factors are associated with menopause and influenced by substitutive hormonal therapy in a cohort of French women. Atherosclerosis 1995 118 123-133.
237. Theintz G, Buchs B, Rizzoli R, Slosman D, Clavien H, Sizonenko PC & Bonjour JP. Longitudinal monitoring of bone mass accumulation in healthy adolescents: evidence for a marked reduction after 16 years of age at the levels of lumbar spine and femoral neck in female subjects. Journal of Clinical Endocrinology and Metabolism 1992 75 1060-1065.
238. Boot AM, de Ridder MA, Pols HA, Krenning EP & Muinck Keizer-Schrama SM. Bone mineral density in children and adolescents: relation to puberty, calcium intake, and physical activity. Journal of Clinical Endocrinology and Metabolism 1997 82 57-62.
239. Vaananen HK & Harkonen PL. Estrogen and bone metabolism. Maturitas 1996 23 (Suppl) S65-S69.
240. Prior JC, Vigna YM, Wark JD, Eyre DR, Lentle BC, Li DK, Ebeling PR & Atley L. Premenopausal ovariectomy-related bone loss: a randomized, double-blind, one-year trial of conjugated estrogen or medroxyprogesterone acetate. Journal of Bone Mineral Research 1997 12 1851-1863.
241. Mullis PE, Yoshimura N, Kuhlmann B, Lippuner K, Jaeger P & Harada H. Aromatase deficiency in a female who is compound heterozygote for two new point mutations in the P450arom gene: impact of estrogens on hypergonadotropic hypogonadism, multicystic ovaries, and bone densitometry in childhood. Journal of Clinical Endocrinology and Metabolism 1997 82 1739-1745.
242. Brown DM, Jowsey J & Bradford DS. Osteoporosis in ovarian dysgenesis. Journal of Pediatrics 1974 84 816-820.
243. Stepan JJ, Musilova J & Pacovsky V. Bone demineralization, biochemical indices of bone remodeling, and estrogen replacement therapy in adults with Turner's syndrome. Journal of Bone Mineral Research 1989 4 193-198.
244. Shore RM, Chesney RW, Mazess RB, Rose PG & Bargman GJ. Skeletal demineralization in Turner's syndrome. Calcified Tissue International 1982 34 519-522.
245. Kurabayashi T, Yasuda M, Fujimaki T, Yamamoto Y, Oda K & Tanaka K. Effect of hormone replacement therapy on spinal bone mineral density and T lymphocyte subsets in premature ovarian failure and Turner's syndrome. International Journal of Gynaecology and Obstetrics 1993 42 25-31.
246. Davies MC, Gulekli B & Jacobs HS. Osteoporosis in Turner's syndrome and other forms of primary amenorrhoea. Clinical Endocrinology 1995 43 741-746.
247. Sylven L, Hagenfeldt K & Ringertz H. Bone mineral density in middle-aged women with Turner's syndrome. European Journal of Endocrinology 1995 132 47-52.
248. Garden AS, Diver MJ & Fraser WD. Undiagnosed morbidity in adult women with Turner's syndrome. Clinical Endocrinology 1996 45 589-593.
249. Landin-Wilhelmsen K, Bryman I, Windh M & Wilhelmsen L. Osteoporosis and fractures in Turner syndrome - importance of growth promoting and oestrogen therapy. Clinical Endocrinology 1999 51 497-502.
250. Pors NS, Kolthoff N, Barenholdt O, Kristensen B, Abrahamsen B, Hermann AP & Brot C. Diagnosis of osteoporosis by planar bone densitometry: can body size be disregarded? British Journal of Radiology 1998 71 934-943.
251. Saggese G, Federico G, Bertelloni S & Baroncelli GI. Mineral metabolism in Turner's syndrome: evidence for impaired renal vitamin D metabolism and normal osteoblast function. Journal of Clinical Endocrinology and Metabolism 1992 75 998-1001.
252. Saggese G, Bertelloni S, Baroncelli GI & Federico G. Assessment of thyroidal 'C' cell secretion in osteoporotic girls with Turner's syndrome. Basal and calcium-stimulated levels of total calcitonin, extractable calcitonin and katakalcin. Acta Peadiatrica 1992 81 532-535.
253. Naeraa RW, Brixen K, Hansen RM, Hasling C, Mosekilde L, Andresen JH, Charles P & Nielsen J. Skeletal size and bone mineral content in Turner's syndrome: relation to karyotype, estrogen treatment, physical fitness, and bone turnover. Calcified Tissue International 1991 49 77-83.
254. Ross JL, Long LM, Feuillan P, Cassorla F & Cutler GB Jr. Normal bone density of the wrist and spine and increased wrist fractures in girls with Turner's syndrome. Journal of Clinical Endocrinology and Metabolism 1991 73 355-359.
255. Preger L, Steinbach HL, Moskowitz P, Scully AL & Goldberg MB. Roentgenographic abnormalities in phenotypic females with gonadal dysgenesis. A comparison of chromatin positive patients and chromatin negative patients. American Journal of Roentgenology, Radium Therapy, and Nuclear Medicine 1968 104 899-910.
256. Smith MA, Wilson J & Price WH. Bone demineralisation in patients with Turner's syndrome. Journal of Medical Genetics 1982 19 100-103.
257. Marshall D, Johnell O & Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. British Medical Journal 1996 312 1254-1259.
258. Mora S, Weber G, Guarneri MP, Nizzoli G, Pasolini D & Chiumello G. Effect of estrogen replacement therapy on bone mineral content in girls with Turner syndrome. Obstetrics and Gynecology 1992 79 747-751.
259. Mauras N, Vieira NE & Yergey AL. Estrogen therapy enhances calcium absorption and retention and diminishes bone turnover in young girls with Turner's syndrome: a calcium kinetic study. Metabolism 1997 46 908-913.
260. Emans SJ, Grace E, Hoffer FA, Gundberg C, Ravnikar V & Woods ER. Estrogen deficiency in adolescents and young adults: impact on bone mineral content and effects of estrogen replacement therapy. Obstetrics and Gynecology 1990 76 585-592.
261. Carrascosa A, Gussinye M, Terradas P, Yeste D, Audi L & Vicens-Calvet E. Spontaneous, but not induced, puberty permits adequate bone mass acquisition in adolescent Turner syndrome patients. Journal of Bone Mineral Research 2000 15 2005-2010.
262. Gravholt CH, Vestergaard P, Hermann AP, Mosekilde L, Brixen K & Christiansen JS. Increased fracture rates in Turner's syndrome: a nationwide questionnaire survey. Clinical Endocrinology 2003 59 89-96.
263. Khastgir G, Studd JW, Fox SW, Jones J, Alaghband-Zadeh J & Chow JW. A longitudinal study of the effect of subcutaneous estrogen replacement on bone in young women with Turner's syndrome. Journal of Bone Mineral Research 2003 18 925-932.
264. Ivarsson SA, Ericsson UB, Nilsson KO, Gustafsson J, Hagenas L, Hager A, Moell C, Tuvemo T, Westphal O & Albertsson Wikland K. Thyroid autoantibodies, Turner's syndrome and growth hormone therapy. Acta Peadiatrica 1995 84 63-65.
265. Van Campenhout J, Antaki A & Rasio E. Diabetes mellitus and thyroid autoimmunity in gonadal dysgenesis. Fertility and Sterility 1973 24 1-9.
266. Williams ED, Engel E & Forbes AP. Thyrolditis and gonadal dysgenesis. New England Journal of Medicine 1964 270 805-810.
267. Pai GS, Leach DC, Weiss L, Wolf C & Van Dyke DL. Thyroid abnormalities in 20 children with Turner syndrome. Journal of Pediatrics 1977 91 267-269.
268. Bright GM, Blizzard RM, Kaiser DL & Clarke WL. Organ-specific autoantibodies in children with common endocrine diseases. Journal of Pediatrics 1982 100 8-14.
269. Germain EL & Plotnick LP. Age-related anti-thyroid antibodies and thyroid abnormalities in Turner syndrome. Acta Paediatrica Scandinavica 1986 75 750-755.
270. Fleming S, Cowell C, Bailey J & Burrow GN. Hashimoto's disease in Turner's syndrome. Clinical and Investigative Medicine 1988 11 243-246.
271. Gruneiro PL, Iorcansky S, Coco R, Rivarola MA & Bergada C. High incidence of thyroid disturbances in 49 children with Turner syndrome. Journal of Pediatrics 1987 111 258-261.
272. Radetti G, Mazzanti L, Paganini C, Bernasconi S, Russo G, Rigon F & Cacciari E. Frequency, clinical and laboratory features of thyroiditis in girls with Turner's syndrome. The Italian Study Group for Turner's Syndrome. Acta Peadiatrica 1995 84 909-912.
273. Marner B, Bille G, Christy M, Damsgaard EM, Garne S, Heinze E, Larsen S, Lernmark A, Mandrup PT & Nerup J. Islet cell cytoplasmic antibodies (ICA) in diabetes and disorders of glucose tolerance. Diabetic Medicine 1991 8 812-816.
274. Larizza D, Martinetti Bianchi M, Lorini R, Maghnie M, Dugoujon JM, Cuccia Belvedere M & Severi F. Autoimmunity, HLA, Gm and Km polymorphisms in Turner's syndrome. Autoimmunity 1989 4 69-78.
275. Chiovato L, Larizza D, Bendinelli G, Tonacchera M, Marino M, Mammoli C, Lorini R, Severi F & Pinchera A. Autoimmune hypothyroidism and hyperthyroidism in patients with Turner's syndrome. European Journal of Endocrinology 1996 134 568-575.
276. Gravholt CH, Klausen IC, Weeke J & Christiansen JS. Lp(a) and lipids in adult Turner's syndrome: impact of treatment with 17 beta-estradiol and norethisterone. Atherosclerosis 2000 150 201-208.
277. Dean JW & Fowler PB. Exaggerated responsiveness to thyrotrophin releasing hormone: a risk factor in women with coronary artery disease. British Medical Journal 1985 290 1555-1561.
278. Arem R & Patsch W. Lipoprotein and apolipoprotein levels in subclinical hypothyroidism. Effect of levothyroxine therapy. Archives of Internal Medicine 1990 150 2097-2100.
279. Arem R & Escalante D. Subclinical hypothyroidism: epidemiology diagnosis and significance. In Advances in Internal Medicine, pp 213-250. Ed. RW Schrier. St. Louis, MO, USA: Mosby, 1996.
280. Bonamico M, Pasquino AM, Mariani P, Danesi HM, Culasso F, Mazzand L, Petri A & Bona G. Prevalence and clinical picture of celiac disease in Turner syndrome. Journal of Clinical Endocrinology and Metabolism 2002 87 5495-5498.
281. Gupta S, Chiplunkar S, Gupta A & Gollapudi S. Increased spontaneous, tumor necrosis factor receptor- and CD95 (Fas)-mediated apoptosis in cord blood T-cell subsets from Turner's syndrome. Genes and Immunity 2003 4 239-243.
282. Jensen K, Petersen PH, Nielsen EL, Dahl G & Nielsen J. Serum immunoglobulin M, G, and A concentration levels in Turner's syndrome compared with normal women and men. Human Genetics 1976 31 329-334.
283. Lorini R, Ugazio AG, Cammareri V, Larizza D, Castellazzi AM, Brugo MA & Severi F. Immunoglobulin levels, T-cell markers, mitogen responsiveness and thymic hormone activity in Turner's syndrome. Thymus 1983 5 61-66.
284. Cacciari E, Masi M, Fantini MP, Licastro F, Cicognani A, Pirazzoli P, Villa MP, Specchia F, Forabosco A, Franceschi C & Martoni L. Serum immunoglobulins and lymphocyte subpopulations derangement in Turner's syndrome. Journal of Immunogenetics 1981 8 337-344.
285. al Attas RA, Rahi AH & Ahmed E. Common variable immunodeficiency with CD4 + T lymphocytopenia and overproduction of soluble IL-2 receptor associated with Turner's syndrome and dorsal kyphoscoliosis. Journal of Clinical Pathology 1997 50 876-879.
286. Robson SC & Potter PC. Common variable immunodeficiency in association with Turner's syndrome. Journal of Clinical and Laboratory Immunology 1990 32 143-146.
287. Nienhuis HE, Rongen Westerlaken C, Geertzen HG, Rijkers GT, Zegers BJ & Wit JM. Long-term effect of human growth hormone therapy on the prevalence of autoantibodies in Turner syndrome. The Dutch Growth Hormone Working Group. Hormone Research 1993 39 (Suppl 2) 49-53.
288. Mauras N. Estrogens do not affect whole-body protein metabolism in the prepubertal female. Journal of Clinical Endocrinology and Metabolism 1995 80 2842-2845.
289. Reschini E, D'Alberton A, Catania A & Motta T. Growth hormone and ACTH secretory dynamics in Turner's syndrome. Gynecological Endocrinology 1990 4 119-125.
290. Lucky AW, Marynick SP, Rebar RW, Cutler GB, Glen M, Johnsonbaugh RE & Loriaux DL. Replacement oral ethinyl oestradiol therapy for gonadal dysgenesis: growth and adrenal androgen studies. Acta Endocrinologica 1979 91 519-528.
291. Balducci R, Toscano V, Larizza D, Mangiantini A, Galasso C, Municchi G, Di-Rito A, Picone S & Boscherini B. Effects of long-term growth hormone therapy on adrenal steroidogenesis in Turner syndrome. Hormone Research 1998 49 210-215.
292. Larizza D, Cuccia M, Martinetti M, Maghnie M, Dondi E, Salvaneschi L & Severi F. Adrenocorticotrophin stimulation and HLA polymorphisms suggest a high frequency of heterozygosity for steroid 21-hydroxylase deficiency in patients with Turner's syndrome and their families. Clinical Endocrinology 1994 40 39-45.
293. Martin DD, Schweizer R, Schwarze CP, Elmlinger MW, Ranke MB & Binder G. The early dehydroeplandrosterone sulfate rise of adrenarche and the delay of pubarche indicate primary ovarian failure in Turner syndrome. Journal of Clinical Endocrinology and Metabolism 2004 89 1164-1168.
294. Naeraa RW, Nielsen J & Kastrup KW. Growth hormone and 17 beta-oestradiol treatment of Turner girls - 2-year results. European Journal of Pediatrics 1994 153 72-77.
295. Rosenfeld RG, Frane J, Attie KM, Brasel JA, Burstein S, Cara JF, Chernausek S, Gotlin RW, Kuntze J & Lippe BM. Six-year results of a randomized, prospective trial of human growth hormone and oxandrolone in Turner syndrome. Journal of Pediatrics 1992 121 49-55.
296. Sylven L, Hagenfeldt K, Brondum NK & von Schoultz B. Middle-aged women with Turner's syndrome. Medical status, hormonal treatment and social life. Acta Endocrinologica 1991 125 359-365.
297. Gardner LI. Letter: Intrahepatic bile stasis in 45,X Turner's syndrome. New England Journal of Medicine 1974 290 406.
298. Krivosheev AB. [Development of liver cirrhosis in a female patient with Shereshevskii-Turner syndrome]. Klinicheshaia Meditsina 1990 68 95-96.
299. Roulot D, Degott C, Chazouilleres O, Oberti F, Cales P, Carbonell N, Benferhat S, Bresson-Hadni S & Valla D. Vascular involvement of the liver in Turner's syndrome. Hepatology 2004 39 239-247.
300. Invernizzi P, Miozzo M, Battezzati PM, Bianchi I, Graff FR, Simoni G, Selmi C, Watnik M, Gershwin ME & Podda M. Frequency of monosomy X in women with primary biliary cirrhosis. Lancet 2004 363 533-535.
301. Chetkowski RJ, Meldrum DR, Steingold KA, Randle D, Lu JK, Eggena P, Hershman JM, Alkjaersig NK, Fletcher AP & Judd HL. Biologic effects of transdermal estradiol. New England Journal of Medicine 1986 314 1615-1620.
302. Jospe N, Orlowski CC & Furlanetto RW. Comparison of transdermal and oral estrogen therapy in girls with Turner's syndrome. Journal of Pediatric Endocrinology and Metabolism 1995 8 111-116.
303. Guttmann H, Weiner Z, Nikolski E, Ish-Shalom S, Itskovitz-Eldor J, Aviram M, Reisner S & Hochberg Z. Choosing an oestrogen replacement therapy in young adult women with Turner syndrome. Clinical Endocrinology 2001 54 159-164.
304. Van der Hauwaert LG, Fryns JP, Dumoulin M & Logghe N. Cardiovascular malformations in Turner's and Noonan's syndrome. British Heart Journal 1978 40 500-509.
305. Lippe B. Turner syndrome. Endocrinology and Metabolism Clinics of North America 1991 20 121-152.
306. Dawson FKL, Wright AM, Bakker B, Pitlick PT & Rosenfeld RG. Cardiovascular evaluation in Turner syndrome: utility of MR imaging. Australasian Radiology 1992 36 204-209.
307. Gotzsche CO, Krag Olsen B, Nielsen J, Sorensen KE & Kristensen BO. Prevalence of cardiovascular malformations and association with karyotypes in Turner's syndrome. Archives of Diseases in Childhood 1994 71 433-436.
308. Berdahl LD, Wenstrom KD & Hanson JW. Web neck anomaly and its association with congenital heart disease. American Journal of Medical Genetics 1995 56 304-307.
309. Lacro RV, Jones KL & Benirschke K. Coarctation of the aorta in Turner syndrome: a pathologic study of fetuses with nuchal cystic hygromas, hydrops fetalis, and female genitalia. Pediatrics 1988 81 445-451.
310. Clark EB. Neck web and congenital heart defects: a pathogenic association in 45 X-O Turner syndrome? Teratology 1984 29 355-361.
311. Mazzanti L & Cacciari E. Congenital heart disease in patients with Turner's syndrome. Italian Study Group for Turner Syndrome (ISGTS). Journal of Pediatrics 1998 133 688-692.
312. Sybert VP. Cardiovascular malformations and complications in Turner syndrome. Pediatrics 1998 101 E11.
313. Prandstraller D, Mazzanti L, Picchio FM, Magnani C, Bergamaschi R, Perri A, Tsingos E & Cacciari E. Turner's syndrome: cardiologic profile according to the different chromosomal patterns and long-term clinical follow-up of 136 nonpreselected patients. Pediatric Cardiology 1999 20 108-112.
314. Mazzanti L, Prandstraller D, Tassinari D, Rubino I, Santucci S, Picchio FM, Forabosco A & Cacciari E. Heart disease in Turner's syndrome. Helvetica Paediatrica Acta 1988 43 25-31.
315. Lin AE, Lippe B & Rosenfeld RG. Further delineation of aortic dilation, dissection, and rupture in patients with Turner syndrome. Pediatrics 1998 102 e12.
316. Larson EW & Edwards WD. Risk factors for aortic dissection: a necropsy study of 161 cases. American Journal of Cardiology 1984 53 849-855.
317. Natowicz M, Chatten J, Clancy R, Conard K, Glauser T, Huff D, Lin A, Norwood W, Rorke LB & Uri A. Genetic disorders and major extracardiac anomalies associated with the hypoplastic left heart syndrome. Pediatrics 1988 82 698-706.
318. Greenlee R, Hoyme H, Witte M, Crowe P & Witte C. Developmental disorders of the lymphatic system. Lymphology 1993 26 156-168.
319. Carrel L, Cottle AA, Goglin KC & Willard HF. A first-generation X-inactivation profile of the human X chromosome. PNAS 1999 96 14440-14444.
320. Ogata T, Muroya K, Matsuo N, Shinohara O, Yorifuji T, Nishi Y, Hasegawa Y, Horikawa R & Tachibana K. Turner syndrome and Xp deletions: clinical and molecular studies in 47 patients. Journal of Clinical Endocrinology and Metabolism 2001 86 5498-5508.
321. Elsheikh M, Casadei B, Conway GS & Wass JA. Hypertension is a major risk factor for aortic root dilatation in women with Turner's syndrome. Clinical Endocrinology 2001 54 69-73.
322. Verdecchia P, Schillaci G, Gatteschi C, Zampi I, Battistelli M, Bartoccini C & Porcellati C. Blunted nocturnal fall in blood pressure in hypertensive women with future cardiovascular morbid events. Circulation 1993 88 986-992.
323. Ross JL, Feuillan P, Long LM, Kowal K, Kushner H & Cutler GBJ. Lipid abnormalities in Turner syndrome. Journal of Pediatrics 1995 126 242-245.
324. Roberts WC. Aortic dissection: anatomy, consequences, and causes. American Heart Journal 1981 101 195-214.
325. Spittell PC, Spittell JA Jr, Joyce JW, Tajik AJ, Edwards WD, Schaff HV & Stanson AW. Clinical features and differential diagnosis of aortic dissection: experience with 236 cases (1980 through 1990). Mayo Clinic Proceedings 1993 68 642-651.
326. Price WH & Wilson J. Dissection of the aorta in Turner's syndrome. Journal of Medical Genetics 1983 20 61-63.
327. Nielsen J, Sillesen I & Hansen KB. Fertility in women with Turner's syndrome. Case report and review of literature. British Journal of Obstetrics and Gynaecology 1979 86 833-835.
328. Swapp GH, Johnston AW, Watt JL, Couzin DA & Stephen GS. A fertile woman with non-mosaic Turner's syndrome. Case report and review of the literature. British Journal of Obstetrics and Gynaecology 1989 96 876-880.
329. Kaneko N, Kawagoe S & Hiroi M. Turner's syndrome - review of the literature with reference to a successful pregnancy outcome. Gynecologic and Obstetric Investigation 1990 29 81-87.
330. Birdsall M & Kennedy S. The risk of aortic dissection in women with Turner syndrome. Human Reproduction 1996 11 1587.
331. Nagel TC & Tesch LG. ART and high risk patients! Fertility and Sterility 1997 68 748-749.
332. Beauchesne LM, Connolly HM, Ammash NM & Warnes CA. Coarctation of the aorta: outcome of pregnancy. Journal of the American College of Cardiology 2001 38 1728-1733.
333. Weytjens C, Bove T & Van Der Niepen P. Aortic dissection and Turner's syndrome. Journal of Cardiovascular Surgery 2000 41 295-297.
334. Sack MN, Rader DJ & Cannon RO. Oestrogen and inhibition of oxidation of low-density lipoproteins in postmenopausal women. Lancet 1994 343 269-270.
335. Gilligan DM, Quyyumi AA & Cannon RO. Effects of physiological levels of estrogen on coronary vasomotor function in postmenopausal women. Circulation 1994 89 2545-2551.
336. Losordo DW, Kearney M, Kim EA, Jekanowski J & Isner JM. Variable expression of the estrogen receptor in normal and atherosclerotic coronary arteries of premenopausal women. Circulation 1994 89 1501-1510.
337. Selzman CH, Gaynor JS, Turner AS, Johnson SM, Horwitz LD, Whitehill TA & Harken AH. Ovarian ablation alone promotes aortic intimal hyperplasia and accumulation of fibroblast growth factor. Circulation 1998 98 2049-2054.
338. Elsheikh M, Bird R, Casadei B, Conway GS & Wass JA. The effect of hormone replacement therapy on cardiovascular hemodynamics in women with Turner's syndrome. Journal of Clinical Endocrinology and Metabolism 2000 85 614-618.
339. Seely EW, Walsh BW, Gerhard MD & Williams GH. Estradiol with or without progesterone and ambulatory blood pressure in postmenopausal women. Hypertension 1999 33 1190-1194.
340. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988 37 1595-1607.
341. Naeraa RW, Gravholt CH, Hansen J, Nielsen J & Juul S. Mortality in Turner syndrome. In Turner Syndrome in a Life Span Perspective: Research and Clinical Aspects, p 323. Eds K Albertsson-Wikland & MB Ranke. Amsterdam: Elsevier, 1995.
342. Scarfi MR, Prisco F, Bersani F, Lioi MB, Zeni O, Di Pietro R, Franceschi C, Motta M, Iafusco D & Stoppoloni G. Spontaneous and mitomycin-C-induced micronuclei in lymphocytes from subjects affected by Turner's syndrome. Mutation Research 1996 357 183-190.
343. Kveiborg M, Gravholt CH & Kassem M. Evidence of a normal mean telomere fragment length in patients with Ullrich-Turner syndrome. European Journal of Human Genetics 2001 9 877-879.
344. Fang J, Dagenais SL, Erickson RP, Arlt MF, Glynn MW, Gorski JL, Seaver LH & Glover TW. Mutations in FOXC2 (MFH-1), a forkhead family transcription factor, are responsible for the Hereditary Lymphedema-Distichiasis syndrome. American Journal of Human Genetics 2000 67 1382-1388.
345. Phillips DI, Barker DJ, Hales CN, Hirst S & Osmond C. Thinness at birth and insulin resistance in adult life. Diabetologia 1994 37 150-154.
346. Cook JT, Levy JC, Page RC, Shaw JA, Hattersley AT & Turner RC. Association of low birth weight with beta cell function in the adult first degree relatives of non-insulin dependent diabetic subjects [see comments]. British Medical Journal 1993 302-306.
347. Phipps K, Barker DJ, Hales CN, Fall CH, Osmond C & Clark PM. Fetal growth and impaired glucose tolerance in men and women. Diabetologia 1993 36 225-228.
348. Robinson S, Walton RJ, Clark PM, Barker DJ, Hales CN & Osmond C. The relation of fetal growth to plasma glucose in young men. Diabetologia 1992 35 444-446.
349. Hales CN, Barker DJ, Clark PM, Cox LJ, Fall C, Osmond C & Winter PD. Fetal and infant growth and impaired glucose tolerance at age 64. British Medical Journal 1991 303 1019-1022.
350. Boman UW, Bryman I, Halling K & Moller A. Women with Turner syndrome: psychological well-being, self-rated health and social life. Journal of Psychosomatic Obstetrics and Gynaecology 2001 22 113-122.
351. Miller MJ, Geffner ME, Lippe BM, Itami RM, Kaplan SA, DiSessa TG, Isabel-Jones JB & Friedman WF. Echocardiography reveals a high incidence of bicuspid aortic valve in Turner syndrome. Journal of Pediatrics 1983 102 47-50.